THALES
17.6.2024 09:01:34 CEST | Business Wire | Press release
To create trusted generative AI solutions, Thales’s cortAIx Lab, the most powerful integrated laboratory for critical AI in Europe, and the CEA, which is one of the world’s most innovative research organisations and is listed alongside Thales in the Clarivate Analytics Top 100 Global Innovators,1 have joined forces to focus on a range of generative AI use cases, in particular for intelligence and command applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240617313286/en/
Alexandre Bounouh, Director of the CEA-List Institute, specialising in smart digital systems, and Bertrand Tavernier, CTO for Thales’s Secure Communications and Information Systems business, at the signing of the partnership agreement on 30 April 2024 in Palaiseau, France. (Photo: Thales)
Bertrand Tavernier, Chief Technical Officer for Thales’s Secure Communications and Information Systems business: “This partnership with the CEA’s AI teams will combine the power of their research with our work at cortAIx, Thales’s AI accelerator, which brings together the Group’s technological expertise and deep knowledge of the defence and security sectors. Our customers — governments, armed forces, critical infrastructure operators — need trusted, sovereign generative AI solutions for their critical missions.”
Alexandre Bounouh, Director of the CEA’s List Institute, specialising in smart digital systems: “This partnership builds on the long-standing collaboration between the CEA and Thales and extends it to the sensitive issue of generative AI, combining the expertise and excellence of the CEA’s research teams in AI safety and security with cortAIx’s strengths in the strategic domain of defence and security. It will support the CEA’s mission in safety, security and artificial intelligence with our partners and all institutional and industry stakeholders in this field.”
Use cases for the armed forces
Generative AI can be developed to accelerate OODA command loops (observe, orient, decide, act) and implemented across the entire critical decision chain: sensing and data gathering, data transmission and storage, data processing and decision support.
Generative AI will serve as a trusted smart assistant for users, enabling them to dialogue easily and efficiently with complex systems with the aim of facilitating and accelerating human decision-making and the tempo of operations. For intelligence gathering, for example, multimodal generative AI will make it possible to simultaneously extract, process, correlate and interpret different types of information from multiple sources — such as the web, social media and sensors in a theatre of operations — to generate summaries and accelerate the production of reliable reports.
Thales’s cortAIx Lab and the CEA will also focus on interoperability within coalitions. To simplify communication between member states in the context of a joint operation, trusted generative AI will facilitate interaction between operators and complex systems by translating their intentions into a sequence of actions and translating technical terms into the languages of the various nations involved.
Thales, a leader in trusted AI for mission-critical systems
Thales is a major player in trusted, cybersafe, transparent, explainable and ethical AI for armed forces, aircraft manufacturers and critical infrastructure operators. In 2023, the Group was Europe’s top patent applicant in the field of AI for mission-critical systems. It has more than 600 AI experts and hosts around 100 PhD students every year in AI at cortAIx, Thales’s AI accelerator in the field of research (cortAIx Lab), systems (cortAIx Factory for decision support systems) and sensors (cortAIx Sensors for sonar, radar, radio and optronics). Thanks to cortAIx and its network of world-class industry, start-up and academic partners, Thales is building AI into more than 100 of its products and services. Benefiting from the most advanced sensor and system technologies, these AI capabilities cover the full spectrum of needs in defence, aviation, space, cybersecurity and digital identity. Trusted AI is designed to meet the specific security and sovereignty needs of Thales’s customers. It brings greater efficiency to data analysis and decision support and speeds up the detection, identification and classification of objects of interest and target scenes, while taking account of specific constraints such as cybersecurity, embeddability and frugality in critical environments.
CEA, a key player in trusted AI for mission-critical systems
In the field of artificial intelligence, the CEA is uniquely positioned across the entire AI value chain, with skills ranging from algorithms and software development tools to computing architectures and microelectronics. The hardware and software solutions developed by the CEA with its academic and industry partners are aimed at applications where AI quality and performance are critical. They include sovereign applications for which the CEA is its own customer (cybersecurity, defence, energy) and industrial applications to which the CEA contributes its expertise.
The CEA has developed high-level expertise in AI technologies, enabling the agency to support its industry partners in the development of innovative solutions. At its CEA-List Institute specialising in smart digital systems, the CEA focuses its research on the development of high-performance, trusted and sovereign models.
Working with Thales, the CEA teams will be applying their expertise more specifically to develop LLMs (large language models) and VLMs (vision language models) for the sectors and use cases targeted by Thales.
About Thales Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity. It develops products and solutions that help make the world safer, greener and more inclusive. The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G. Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion. |
About CEA
The CEA is a major research organisation working in the best interests of the French State, its economy and citizens. Thanks to its strong roots in fundamental research, it is able to provide tangible solutions to meet their needs in four key fields: low-carbon energy, digital technologies, technologies for medicine of the future, defence and national security. As the world’s leading innovator among public research organisations (Clarivate 2024), the CEA acts as a catalyst and accelerator of innovation for French industry. It helps businesses in all sectors be more competitive, creating high-performance products that stand out from the crowd and developing trail-blazing solutions that lead to changes in society. The CEA deploys this dynamic in all regions of France aiding local partners to innovate themselves, thus helping to create sustainable value and jobs nationwide, tailored to meet actual industry needs. At the same time, it supports the development of its 250 start-ups, agile vectors for transferring the disruptive technology and knowledge developed at CEA laboratories to industry.
Find out more: www.cea.fr
PLEASE VISIT
Thales Group
Security
Thales
@Thalesgroup
___________________________
1 The CEA is listed with Thales in the Top 100 Global Innovators published by Clarivate Analytics: Thales listed among world’s top 100 most innovative companies for 11 time | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240617313286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
